Eisai's eribulin misses the capecitabine mark in second-line breast cancer
This article was originally published in Scrip
After an initial 3.3% drop, shares in Eisai closed down by 1.0% in Tokyo on 10 July as the company disclosed that Halaven (eribulin) missed both primary survival endpoints in a comparative Phase III trial as a second-line therapy for advanced breast cancer.
You may also be interested in...
Japan approval for BTK inhibitor marks new indication but in a small niche market, while another clearance may help extend Latuda's commercial life.
Novel antibody-drug conjugate receives approval in Japan for second-line breast cancer, providing another push to Japanese firm’s strategic plan to build up its oncology operations.
Collaboration with fundraising Tokyo-based venture builds mid-sized firm's interest in cell-based therapies in a highly supportive regulatory environment.